Home >> Life Sciences >> Diagnostics >> In Vitro Diagnostics >> Hematology & Oncology

Pontine Glioma - Pipeline Review, H1 2017

Published: Jun-2017 | Format: PDF | Global Markets Direct | Number of pages: 148 | Code: MRS - 139844

Pontine Glioma - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Pipeline Review, H1 2017, provides an overview of the Pontine Glioma (Oncology) pipeline landscape.

Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing.  

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pontine Glioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pontine Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pontine Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 5, 7 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 2 molecules, respectively.

Pontine Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pontine Glioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pontine Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pontine Glioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pontine Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Pontine Glioma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pontine Glioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pontine Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pontine Glioma - Overview
Pontine Glioma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pontine Glioma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pontine Glioma - Companies Involved in Therapeutics Development
AbbVie Inc
Arog Pharmaceuticals Inc
AstraZeneca Plc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Burzynski Research Institute Inc
Insys Therapeutics Inc
Loxo Oncology Inc
Medicenna Therapeutics Corp
Midatech Pharma Plc
Novogen Ltd
Ono Pharmaceutical Co Ltd
Pfizer Inc
Sanofi
ZIOPHARM Oncology Inc
Pontine Glioma - Drug Profiles
(A-10 + AS-21) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AdRTSIL-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
afatinib dimaleate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-1775 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabazitaxel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crenolanib besylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
depatuxizumab mafodotin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ipilimumab + nivolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larotrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDNA-55 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugate to Target B7H3 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTX-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTX-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nivolumab - Drug Profile
R&D Progress
ORX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
p28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pidilizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Trilexium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIMO-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pontine Glioma - Dormant Projects
Pontine Glioma - Product Development Milestones
Featured News & Press Releases
Jul 11, 2016: AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma (DIPG)
Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant
Jun 04, 2015: Studies Confirm TRXE-009 Crosses the Blood-brain Barrier
May 08, 2015: Australian Studies Confirm TRXE-009 Kills Resistant Paediatric Brain Cancer Cells
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

                        
            

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

Single User | $(USD)2000 View Pricing